In the BioHarmony Drug Report Database
Talimogene laherparepvec
Imlygic (talimogene laherparepvec) is a gene pharmaceutical. Talimogene laherparepvec was first approved as Imlygic on 2015-12-16. It is used to treat melanoma in the USA. It has been approved in Europe to treat melanoma.
Trade Name
|
Imlygic |
|---|---|
Common Name
|
talimogene laherparepvec |
ChEMBL ID
|
CHEMBL2108727 |
Indication
|
melanoma |
Drug Class
|
Image (chem structure or protein)
